The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 28, 2015

Filed:

Apr. 14, 2010
Applicants:

Samarenda K. Mohanty, Irvine, CA (US);

Matthew Ficinski, Baldwin Park, CA (US);

Edward K. Wong, Newport Beach, CA (US);

Michael W. Berns, Bonsall, CA (US);

Inventors:

Samarenda K. Mohanty, Irvine, CA (US);

Matthew Ficinski, Baldwin Park, CA (US);

Edward K. Wong, Newport Beach, CA (US);

Michael W. Berns, Bonsall, CA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61N 1/32 (2006.01); A61N 1/04 (2006.01); A61F 9/00 (2006.01); A61K 9/00 (2006.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
A61N 1/327 (2013.01); A61N 1/0412 (2013.01); A61F 9/0017 (2013.01); A61K 9/0048 (2013.01); A61K 38/177 (2013.01); A61N 1/0416 (2013.01);
Abstract

An apparatus for in vivo electroporating a plasmid into a retina of any eye includes a first electrode with a first polarity of voltage placed in contact with a cornea of the eye, a second electrode with an opposite second voltage at least in part behind the retina, and a pulsed voltage source for providing a pulsed DC voltage with an optimized field strength amplitude, frequency, number of pulses, group repetition rate and duration of pulse and group repetition, which are optimized for transfection of the channelrhodospsin-2 (ChR2) gene into the retinal ganglion cells. An in vivo method for treating retinal ganglion cells in an eye without use of viral transfection includes the steps of nonviral in vivo delivering a channelrhodospsin-2 (ChR2) gene to target the specific (retinal ganglion) cells of a retina by intravitreous injection of plasmid DNA, electroporating the plasmid into the retina and use of image intensification device for stimulating the retinal ganglion cells with ambient lighting conditions.


Find Patent Forward Citations

Loading…